Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: A series of six cases

British Journal of Dermatology

Volumn 156, Issue SUPPL. 3, 2007, Pages 40-42

  Ulrich, C ^a   Hackethal, M ^a   Ulrich, M ^a   Howorka, A ^a   Forschner, T ^a   Sterry, W ^a   Stockfleth, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Actinic keratosis; Diclofenac 3 gel; Organ transplant recipients

Indexed keywords

DICLOFENAC;

ACTINIC KERATOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EROSION; ERYTHEMA; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER GRAFT; ORGAN TRANSPLANTATION; PATIENT ASSESSMENT; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; GELS; HUMANS; IMMUNOCOMPROMISED HOST; KERATOSIS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 34247359625     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07864.x     Document Type: Article

References (15)

1. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000 342 : 605 12.
2. Kasiske BL, Snyder JJ, Gibertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4 : 905 13.
3. Ismail F, Mitchell L, Casabonne D et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006 155 : 916 25.
4. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999 397 : 530 4.
5. Kovach BT, Stasko T. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther 2005 18 : 19 27.
6. Nijsten T, Colpaert CG, Vermeulen PB et al. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004 151 : 837 45.
7. Seed MP, Brown JR, Freemantle CN et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997 57 : 1625 9.
8. Cortes R. Correspondence. Int J Dermatol 2002 44 : 371 3.
9. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002 146 : 94 100.
10. Wolf J, Taylor J, Tschen E et al. Topical 3% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001 40 : 709 13.
11. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Aust J Dermatol 2003 44 : 40 45.
12. Smith S, Morhenn V, Piacquadio J. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006 5 : 156 9.
13. Ulrich C, Busch JO, Meyer T et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006 155 : 451 4.
14. De Graaf YG, Kennedy C, Wolterbeek R et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006 126 : 569 74.
15. Oseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol 2006 126 : 542 4.